Isomorphic Labs
Contact SalesAI-powered drug discovery beyond AlphaFold to solve all disease
By Tanmay Verma, Founder · Last verified 03 Jun 2026
7.4k views
Added 9d ago
76/100Safe BetAI-powered drug discovery beyond AlphaFold to solve all disease
By Tanmay Verma, Founder · Last verified 03 Jun 2026
Affiliate disclosure: We earn a commission when you use our links. Editorial picks are independent. How we choose.
A bold, AI-native drug discovery company leveraging AlphaFold heritage. Best for organizations seeking cutting-edge AI to accelerate therapeutic development, but its platform is not publicly available—only through partnerships.
Compare with: Isomorphic Labs vs Recursion, Isomorphic Labs vs Owkin, Isomorphic Labs vs Brave Search
Last verified: June 2026
Isomorphic Labs is a high-risk, high-reward bet on AI transforming pharma. Pick this if you're a large pharma company wanting to license next-generation drug design engines or collaborate on specific targets. The Drug Design Engine, built on AlphaFold's legacy, promises to unlock a new frontier in digital biology. However, pass if you need a ready-to-use SaaS tool—the platform is likely offered only through direct partnerships and licensing deals. Compared to competitors like Recursion Pharmaceuticals or Insilico Medicine, Isomorphic Labs benefits from DeepMind's pedigree and the AlphaFold brand, but its closed, partnership-based model limits accessibility. Real-world caveats: the technology is still evolving, and no drug candidates have been publicly disclosed yet. Expect long timelines before clinical impact.
Skip Isomorphic Labs if Skip Isomorphic Labs if you are an individual researcher or a small startup without a partnership agreement with a major pharma company.
Isomorphic Labs closed a Series B investment round. Amount and details not disclosed.
Isomorphic Labs partnered with Johnson & Johnson for AI-driven drug discovery.
How likely is Isomorphic Labs to still be operational in 12 months? Based on 6 signals including funding, development activity, and platform risk.
Isomorphic Labs is reimagining drug discovery by combining frontier AI with deep biological insights. Building on the Nobel-winning AlphaFold system, the company develops predictive and generative AI models that accelerate the design of novel molecules and the development of life-changing medicines. Ideal for pharmaceutical researchers and biotech innovators, Isomorphic Labs offers a Drug Design Engine that goes beyond AlphaFold to model complex biological phenomena and anticipate drug performance. Key capabilities include AI-driven molecular design, predictive modeling of drug behavior, and generative models for novel therapeutics. With partnerships like the collaboration with Johnson & Johnson, Isomorphic Labs positions itself as a leader in digital biology, distinct from traditional pharma R&D by its AI-first approach.
Tell us what you want to build — we'll match the AI tools that fit your goal, budget & existing stack.
Concrete scenarios for the personas Isomorphic Labs actually fits — and what changes day-one when you adopt it.
A lead at a large pharma wants to identify novel drug targets for an unmet medical need. The team partners with Isomorphic Labs to use AlphaFold for protein structure prediction and AI-driven target identification.
Outcome: Within weeks, the collaboration yields validated target candidates with predicted binding sites, enabling rapid entry into hit discovery.
A scientist at a biotech partnered with Isomorphic Labs needs to design molecules with optimized binding affinity for a known target.
Outcome: Using the Drug Design Engine, the scientist generates and screens thousands of candidate molecules in silico, prioritizing the top 50 for synthesis and testing, reducing early-stage cycle time by months.
Isomorphic Labs is not a publicly available tool; it operates through research collaborations with pharmaceutical companies. Access is gated by partnership agreements, making it inaccessible to individual users or small teams. There are no self-service tiers, public API, or pricing plans. The platform focuses on partnership-driven projects, limiting its use to organizations with substantial resources and long-term commitment.
The company stage and team size where Isomorphic Labs's pricing actually pencils out — and where peers do it cheaper.
Pricing is contact-only and negotiated per partnership. There is no published tier or list price. Compared to academic tools like open-source AlphaFold, this is a premium, enterprise-only service. For large pharma with multi-million-dollar R&D budgets, the value lies in accelerated timelines. Smaller entities may find it prohibitively expensive or inaccessible.
How long it actually takes to get something useful out of Isomorphic Labs — broken out by persona, not the marketing-page minute.
Setup time depends on partnership negotiation and data integration. For a new collaboration, expect several months to finalize legal agreements, integrate proprietary data, and train models on partner-specific targets. Existing partners may see initial results within weeks.
How to bring data in from common predecessors and how to get it back out — written for the switcher, not the buyer.
Pricing, brand, ownership, or deprecation changes worth knowing before you commit. Most-recent first.
Common stack mates teams adopt alongside Isomorphic Labs, with the specific reason each pairing earns its keep.
Used Isomorphic Labs? Help shape our editorial sentiment research.
© 2026 RightAIChoice. All rights reserved.
Built for the AI community.
Max Jaderberg appointed President of Isomorphic Labs, effective at a future date.
Last calculated: May 2026
Private search engine with independent index, AI answers, and no tracking.
